Use of bisphosphonates for the treatment of bone metastasis in experimental animal models

Cancer Treatment Reviews

Volumn 25, Issue 5, 1999, Pages 293-299

  Yoneda, T ^a,b   Michigami, T ^a   Yi, B ^a   Williams, P J ^a   Niewolna, M ^a   Hiraga, T ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Bisphosphonates; Breast cancer; Osteoclasts; Osteolytic bone metastasis; Osteosclerotic bone metastasis; Prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; INCADRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TEGAFUR; UFT; ZOLEDRONIC ACID;

ADRENAL METASTASIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; BONE METASTASIS; BREAST CANCER; CANCER INHIBITION; CANCER SURVIVAL; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOSCLEROSIS; PROSTATE CANCER; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032723813     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.1999.0133     Document Type: Review

References (38)

1. Hortobagyi G. N., Theriault R. L., Porter L., Blayney D., Lipton A., Sinoff C., Wheeler H., Simeone J. F., Seaman J., Knight R. D., Heffernan M., Reitsman D. J. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med. 335:1996;1785-1791.
2. Lipton A. Bisphosphonates and breast cancer. Cancer. 80:1997;1668-1673.
3. Adami S. Bisphosphonates in prostate carcinoma. Cancer. 80:1997;1674-1679.
4. Bataille R. Management of myeloma with bisphosphonates. N Engl J Med. 334:1996;529-535.
5. Berenson J. R., Lichtehstein A., Porter L., Dimopoulos M. A., Bordoni R., George S., Lipton A., Keller A., Ballester O., Kovacs M. J., Blacklock H. A., Bell R., Simeone J., Reitsman D. J., Heffernan M., Seaman J., Knight R. D. Efficacy of pamidronate in reducing the skeletal events in patients with advanced multiple myeloma. N Engl J Med. 334:1996;488-493.
6. Berenson J. R. Bisphosphonates in multiple myeloma. Cancer. 80:1997;1661-1667.
7. Bloomfield D. J. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol. 16:1998;1218-1225.
8. Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D. D., Golub E., Rodan G. A. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 88:1991;2095-2105.
9. Mundy G. R., Yoneda T. Facilitation and suppression of bone metastasis. Clin Orthop. 312:1995;34-44.
10. Mundy G. R., Yoneda T. Bisphosphonates as anticancer drug. N Engl J Med. 339:1998;357-363.
11. Yoneda T. Mechanisms of preferential metastasis of breast cancer to bone. Int J Oncol. 9:1996;103-109.
12. Yoneda T. Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone. Eur J Cancer. 34:1998;240-245.
13. Shipman C. M., Rogers M. J., Apperley J. F., Russell R. G. G., Croucher P. I. Bisphosphonate induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol. 98:1997;665-672.
14. Shipman C. M., Croucher P. I., Russell R. G. G., Helfrich M. H., Rogers M. J. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res. 58:1998;5294-5297.
15. Aparicio A., Gardner A., Tu Y., Savage A., Berenson J., Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia. 12:1998;220-229.
16. Coleman R. E., Rubens R. D. The clinical course of bone metastases from breast cancer. Br J Cancer. 55:1987;61-66.
17. Koenders P. G., Beex L. V. A. M., Langens R., Kloppenborg P. W. C., Smals A. G. H., Benraad ThJ. Breast Cancer Res Treat. 18:1991;27-32.
18. Diel I. J., Solomayer E-F., Costa S. D., Gollan C., Goerner R., Wallwiener D., Kaufmann M., Bastert G. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 339:1998;357-363.
19. Body J. J., Bartl R., Burckhardt P., Delmas P. D., Diel I. J., Fleish H., Kanis J. A., Kyle R. A., Mundy G. R., Paterson A. H.G., Rubens R. D. Current use of bisphosphonates in oncology. J Clin Oncol. 16:1998;3890-3899.
20. Theriault R. L., Hortobagyi G. N., Leff R., Gluck S., Stewart J. F., Costello S., Kennedy I., Simeone J., Seaman J. J., Knight R. D., Mellars K., Heffernan M., Reitsman D. J. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. J Clin Oncol. 17:1999;846-854.
21. McCloskey E. V., Powles T., Paterson A. H. G., Ashley S., Kanis J. A. Clodronate reduces incidence of skeletal metastases in women with primary breast cancer. Bone. 23:1998;S189.
22. Milch R. A., Changus G. W. Response of bone to tumor invasion. Cancer. 9:1956;340-351.
23. Kamby C., Andersen J., Ejlertsen B., Birkler N. E., Rytter L., Zedeler K., Thorpe S. M., Norgaard T., Rose C. Histological grade and steroid receptor content of primary breast cancer - impact on prognosis and possible modes of action. Br J Cancer. 58:1988;480-486.
24. Urwin G. H., Percival R. C., Harris S., Beneton M. N. C., Williams J. L., Kanis S. A. Generalized increase in bone resorption in carcinoma of the prostate. Eur J Urol. 57:1985;721-723.
25. Clarke N. W., McClure J., George N. J. R. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol. 68:1991;74-80.
26. Pecherstorfer M., Ludwig H., Zimmer-Roth H., Schiling T., Woitge H. W., Schmidt H., Baumgartner G., Thiebaud D., Ludwig H., Seibel M. J. The diagnostic value of urinary pyridinium cross-links of collagen, alkaline phosphatase and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab. 121:1995;542-548.
27. Yoneda T., Sasaki A., Mundy G. R. Osteolytic bone disease in breast cancer. Breast Cancer Res Treat. 32:1994;73-84.
28. Yoneda T. Arterial microvascularization and breast cancer colonization in bone. Histol Histopathol. 12:1997;1145-1149.
29. Aslakson C. J., Miller F. R. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52:1992;1399-1405.
30. Lelekakis M., Moseley J. M., Martin J. M., Hards D., Williams E., Ho P., Lowen D., Javni J., Miller F. R., Slavin J., Anderson R. L. A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis. 17:1999;163-170.
31. Sasaki A., Boyce B. F., Story B., Wright K. R., Chapman M., Boyce R., Mundy G. R., Yoneda T. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 55:1995;3551-3557.
32. Hughes D. E., Wright K. R., Uy H. L., Sasaki A., Yoneda T., Roodman G. D., Mundy G. R., Boyce B. F. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 10:1995;1478-1487.
33. Fisher J. E., Rogers M. J., Halasy J. M., Luckman S. P., Hughes D. E., Masarachia P. J., Wesolowski G., Russel R. G. G., Rodan G. A., Reszka A. A. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA. 96:1999;133-138.
34. Luckman S. P., Hughes D. E., Coxon F. P., Russell R. G. G., Rogers M. J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-transitional prenylation of GTP-binding proteins, including Ras. J Bone Miner. Res. 13:1998;581-589.
35. Kostenuik P. J., Orr F. W., Suyama K., Singh G. Increased growth rate and tumor burden of spontaneously metastatic Walker 256 cancer cells in the skeleton of bisphosphonates-treated rats. Cancer Res. 53:1993;5452-5457.
36. Stearns M. E., Wang M. Effects of alendronate and taxol on PC-3ML cell bone metastases in SCID mice. Invasion Metastasis. 16:1996;116-131.
37. Takiuchi H., Ajani J. A. Uracil-tegafur in gastric carcinoma: A comprehensive review. J Clin Oncol. 16:1998;2877-2885.
38. Tashiro H., Nomura Y., Ohsaki A. A double blind comparative study of tegafur (FT) and UFT (a comibantion of tegafur and yracil) in advanced breast cancer. Jpn J Clin Oncol. 24:1994;212-217.